Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2017; 38(02): 153-157
DOI: 10.4103/ijmpo.ijmpo_159_16
Original Article

Detection and Significance of Human Epidermal Growth Factor Receptor 2 Expression in Gastric Adenocarcinoma

Sutapa Halder
Department of Pathology, ESI PGIMSR, Manicktala, West Bengal, India
,
Debjani Mallick
Department of Pathology, ESI PGIMSR and ESIC Medical College, Joka, West Bengal, India
,
Priyanka Mondal
Department of Pathology, ESI PGIMSR, Manicktala, West Bengal, India
,
Debajyoti Singha Roy
Department of Pathology, ESI PGIMSR, Manicktala, West Bengal, India
,
Aniket Halder
Department of Pathology, School of Digestive and Liver Diseases, IPGME and R-SSKM Hospitals, Kolkata, West Bengal, India
,
Sudipta Chakrabarti
Department of Pathology, ESI PGIMSR, Manicktala, West Bengal, India
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
  PDF Download Permissions and Reprints

Abstract

Background: Human epidermal growth factor receptor 2 (HER2) is involved in the pathogenesis of several types of cancer, including gastric cancer. Overexpression of HER2 is noted in 10%–22.8% of gastric adenocarcinoma and its identification is of immense importance for management by targeted drugs. Detection of HER2 expression in gastric malignancies has not been undertaken previously in the local population. Objective: To ascertain HER2 immunohistochemical expression in gastric adenocarcinoma and its relationship with the anatomic location and histomorphology. Materials and Methods: A total of 47 cases of gastric adenocarcinoma diagnosed over 2 years constituted the study group. Clinical history, type of operation, gross morphology, and hematoxylin and eosin (H and E) stained sections were reviewed. Two paraffin blocks were selected, immunostain was performed using rabbit monoclonal HER2 antibody and Hoffmann scoring system was applied. Results: Most of gastric carcinomas occurred in male (42 cases), having a mean age of 53.6 years. A total of eight cases (17.1%) had expressed a score of 3+ HER2 positivity. All positivity was noted in intestinal type according to Lauren classification (25%) and none in diffuse type. All HER2 score of 3+ was noted in histological grade of well and moderately differentiated adenocarcinoma. Score 2+ was noted in seven cases, among them, only two were poorly differentiated gastric adenocarcinoma. Conclusion: HER2 overexpression was noticeably associated with an intestinal subtype, and well and moderately differentiated adenocarcinomas. Such cases of gastric adenocarcinoma are considered for targeted therapy with trastuzumab in the local population.

Keywords

Gastric adenocarcinoma - histological grade - human epidermal growth factor receptor 2 expression - human epidermal growth factor receptor 2 score


Publication History

Article published online:
06 July 2021

© 2017. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Fornaro L, Lucchesi M, Caparello C, Vasile E, Caponi S, Ginocchi L, et al. Anti-HER agents in gastric cancer: From bench to bedside. Nat Rev Gastroenterol Hepatol 2011;8:369-83.
  • 2 Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985;230:1132-9.
  • 3 Neve RM, Lane HA, Hynes NE. The role of overexpressed HER2 in transformation. Ann Oncol 2001;12 Suppl 1:S9-13.
  • 4 Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
  • 5 Fukushige S, Matsubara K, Yoshida M, Sasaki M, Suzuki T, Semba K, et al. Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line. Mol Cell Biol 1986;6:955-8.
  • 6 Gómez-Martin C, Garralda E, Echarri MJ, Ballesteros A, Arcediano A, RodrÁguez-Peralto JL, et al. HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer. J Clin Pathol 2012;65:751-7.
  • 7 Jørgensen JT, Hersom M. HER2 as a prognostic marker in gastric cancer – A systematic analysis of data from the literature. J Cancer 2012;3:137-44.
  • 8 Janjigian YY, Werner D, Pauligk C, Steinmetz K, Kelsen DP, Jäger E, et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: A European and USA International collaborative analysis. Ann Oncol 2012;23:2656-62.
  • 9 Gunturu KS, Woo Y, Beaubier N, Remotti HE, Saif MW. Gastric cancer and trastuzumab:First biologic therapy in gastric cancer. Ther Adv Med Oncol 2013;5:143-51.
  • 10 He C, Bian XY, Ni XZ, Shen DP, Shen YY, Liu H, et al. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer. World J Gastroenterol 2013;19:2171-8.
  • 11 De Carli DM, Rocha MP, Antunes LC, Fagundes RB. Immunohistochemical expression of HER2 in adenocarcinoma of the stomach. Arq Gastroenterol 2015;52:152-5.
  • 12 Lakshmi V, Valluru VR, Madhavi J, Valluru N. Role of her 2 neu in gastric carcinoma-3 year study in a medical college hospital. Indian J Appl Res 2014;4:1-4.
  • 13 Sekaran A, Kandagaddala RS, Darisetty S, Lakhtakia S, Ayyagari S, Rao GV, et al. HER2 expression in gastric cancer in Indian population – An immunohistochemistry and fluorescence in situ hybridization study. Indian J Gastroenterol 2012;31:106-10.
  • 14 Ling S, Jianming Y, Ning L. Her 2 expression and relevant clinicopathological features & gastroesophageal junction adenocarcinoma in a Chinese population. Diagn Pathol 2013;8:76.
  • 15 Kunz PL, Mojtahed A, Fisher GA, Ford JM, Chang DT, Balise RR, et al. HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: Clinicopathologic analysis with proposed approach to HER2 assessment. Appl Immunohistochem Mol Morphol 2012;20:13-24.
  • 16 Kataoka Y, Okabe H, Yoshizawa A, Minamiguchi S, Yoshimura K, Haga H, et al. HER2 expression and its clinicopathological features in resectable gastric cancer. Gastric Cancer 2013;16:84-93.
  • 17 Qiu M, Zhou Y, Zhang X, Wang Z, Wang F, Shao J, et al. Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients. BMC Cancer 2014;14:823.
  • 18 Kang Y, Van Cutsem E, Chung H, Shen L, Sawaki A, Lordick F, et al. Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first- line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol 27:18s, 2009 (Suppl; abstr LBA4509).